NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for lung cancer patients: experimental drug takes on standard therapy
Disease control Recruiting nowThis study tests a new drug called rilvegostomig against the standard drug pembrolizumab, both given with chemotherapy, as a first treatment for people with advanced non-squamous lung cancer that has spread. About 878 adults whose tumors have a specific protein (PD-L1) will take …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New Antibody-Drug conjugate enters human trials for advanced cancers
Disease control Recruiting nowThis early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
Disease control Recruiting nowThis phase 3 trial tests whether a combination of an injected virus therapy (CAN-2409) and an immunotherapy drug (pembrolizumab) can help people with stage IV non-squamous non-small cell lung cancer live longer than standard chemotherapy. The virus is designed to kill tumor cells…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug targets Hard-to-Treat cancers with genetic flaw
Disease control Recruiting nowThis study tests a new drug called AZD3470 in people with advanced solid tumors that lack a gene called MTAP. The drug works by blocking a protein that cancer cells need to grow. The trial will check if the drug is safe, tolerable, and effective, both alone and with other cancer …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail aims to outsmart lung cancer
Disease control Recruiting nowThis study tests whether adding an experimental drug called telisotuzumab adizutecan to the standard targeted therapy osimertinib can improve outcomes for people with advanced EGFR-mutated non-small cell lung cancer. About 854 adults will be enrolled worldwide. The trial has two …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for lung cancer patients when targeted drugs stop working
Disease control Recruiting nowThis study tests a new drug called JS207, a bispecific antibody that targets PD-1 and VEGF, in combination with chemotherapy or another experimental drug (JS212) for people with advanced non-small cell lung cancer that has specific gene mutations. The participants have already tr…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug duo targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests a combination of two drugs, BL-M07D1 and pembrolizumab, in people with advanced non-squamous non-small cell lung cancer that has high levels of a protein called HER2. The goal is to see if the combination shrinks tumors and how safe it is. About 80 adults aged 18…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug YL242 takes on advanced solid tumors in first human trial
Disease control Recruiting nowThis study tests a new drug called YL242, given alone or with other treatments, for adults with advanced solid tumors that have not responded to prior therapy. The main goals are to check safety and see if tumors shrink. About 424 participants will take part in this early-phase t…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug YL205 aims to shrink advanced tumors in early trial
Disease control Recruiting nowThis study tests an experimental drug, YL205, in 252 people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and see if it helps shrink tumors. This is …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for HER2-Mutant lung cancer: phase 3 trial launches
Disease control Recruiting nowThis Phase 3 trial is testing a new drug called BL-M07D1 against standard chemotherapy (pembrolizumab plus platinum chemo) as a first treatment for people with advanced or metastatic non-squamous non-small cell lung cancer that has a HER2 mutation. About 440 participants will be …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Brazilian lung cancer study seeks to map Real-World treatment patterns
Knowledge-focused Recruiting nowThis study reviews medical records of 250 adults in Brazil with advanced non-squamous non-small cell lung cancer whose cancer progressed after platinum-based chemotherapy. Researchers will describe patient characteristics, treatments used, and outcomes in routine practice. The go…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC